Articles related to COMBINATION THERAPY

A recent phase 3 trial comparing nivolumab plus AVD to brentuximab vedotin plus AVD in advanced-stage Hodgkin’s lymphoma demonstrated a significant improvement in 2-year progression-free survival (92% vs. 83%, respectively) with a hazard ratio for disease progression or death of 0.45 (95% CI, 0.30 to 0.65).

A phase 3 trial comparing doxorubicin-trabectedin combination therapy to doxorubicin alone in advanced leiomyosarcoma patients demonstrated a median overall survival of 33 months versus 24 months, respectively.

The TOPAZ-1 trial demonstrates that adding durvalumab to standard chemotherapy significantly improves overall survival in patients with advanced biliary tract cancer, potentially establishing a new first-line treatment option for this difficult-to-treat malignancy.

The combination of ponatinib and blinatumomab demonstrated a 95% complete response rate and 91% 3-year overall survival rate in patients with Ph-positive ALL.

The FDA has approved a combination therapy of pembrolizumab, carboplatin, and paclitaxel for advanced endometrial cancer, significantly enhancing progression-free survival rates for patients with both mismatch repair deficient and proficient statuses.

In a phase 3 trial, the combination of amivantamab and lazertinib resulted in a median progression-free survival of 23.7 months, surpassing the 16.6 months observed with osimertinib in patients with EGFR-mutated advanced NSCLC.